Agree - different paths - same conclusion! It is novel to describe an entirely different mechanism of action in the lead to OA, so Paradigm is adding IP value to the medical community in solving this disease. I have a hunch the upcoming peer reviewed journal is to support the patent claim.
I also note the invention covers the need for MRI scans pre and post treatment. This would serve 2 purposes - to foist upon any competitor trying to use PPS to treat OA to prove the patient doesn’t have BME (ie MRI scans have to be undertaken). I would also think MRI scans will be part of the treatment package and will bolster the $1500-$2500 price tag.
Agree - different paths - same conclusion! It is novel to...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $103.1M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 29.5¢ | 28.5¢ | $78.74K | 270.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 76 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 26392 | 6 |
View Market Depth
| Last trade - 15.09pm 08/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |